MVIR
MultiVir

43
Loading...
Loading...
News
all
press releases
Medivir to present updated clinical data for fostrox + Lenvima in HCC at ESMO Conference in September
Medivir to present updated clinical data for fostrox + Lenvima in HCC at ESMO Conference in September Medivir to present updated clinical data for fostrox + Lenvima in HCC at ESMO Conference in...
PR Newswire·1y ago
News Placeholder
More News
News Placeholder
Number of shares and votes in Medivir AB on 28 June 2024
Number of shares and votes in Medivir AB on 28 June 2024 Number of shares and votes in Medivir AB on 28 June 2024 PR Newswire STOCKHOLM, June 28, 2024 STOCKHOLM, June 28, 2024 /PRNewswire/ -- Medivir...
PR Newswire·1y ago
News Placeholder
Fostrox + Lenvima holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI
Fostrox + Lenvima holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI Fostrox + Lenvima holds promise of greatly improved outcomes...
PR Newswire·1y ago
News Placeholder
Medivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility
Medivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility Medivir selects global CRO partner for upcoming phase 2b study in HCC with...
PR Newswire·1y ago
News Placeholder
Medivir to present at Redeye Growth Day
Medivir to present at Redeye Growth Day Medivir to present at Redeye Growth Day PR Newswire STOCKHOLM, May 30, 2024 STOCKHOLM, May 30, 2024 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR) (STOCKHOLM...
PR Newswire·1y ago
News Placeholder
Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI
Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI PR Newswire STOCKHOLM, April 29...
PR Newswire·1y ago
News Placeholder
FDA grants Medivirs MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calv-Perthes Disease
FDA grants Medivirs MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calv-Perthes Disease FDA grants Medivirs MIV-711 Rare Pediatric Disease...
PR Newswire·1y ago
News Placeholder
Medivir's partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701
Medivir's partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701 Medivir's partner Vetbiolix announces positive results from...
PR Newswire·1y ago

Latest MVIR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.